Statin use and survival in elderly patients with endometrial cancer

Yoon, Lara; Goodman, Marc T.; Rimel, B.J.; Jeon, Christie Y.

doi:10.1016/j.ygyno.2015.01.549

Cited by 26 publications

(34 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, there was no dose–response association between the drug groups and endometrial cancer survival. A previous US cohort study using the SEER database of 2987 endometrial cancer patients reported a slightly reduced, although nonsignificant, risk of death (HRs of overall mortality of 0.92) from any cause among patients who used statins compared with those who did not …”

Section: Discussionmentioning

confidence: 91%

An Israeli Gynecologic Oncology Group study of statin use and endometrial cancer prognosis

Segev

Gemer

Helpman

et al. 2019

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Objective To assess whether statin use by endometrial cancer patients was associated with a survival advantage. Methods A retrospective chart review study, by the Israeli Gynecologic Oncology Group, of consecutive endometrial cancer patients who underwent surgery in one of 11 medical centers between 2002 and 2014. Clinical and pathological reports, and measures of survival were compared between statin users and nonusers. Kaplan‐Meier and Cox proportional hazard models were used to assess the effect of using statins on survival measures. Results Over a mean follow‐up period of 6.2 years (range, 1–12 years) for 2017 endometrial cancer patients with complete data, 663 (32.8%) used statins prior to diagnosis and 1354 (67.1%) did not. No statistically significant differences between the groups were observed for most demographic and clinical characteristics. There was no difference between statin users and nonusers in 5‐year recurrence‐free survival (82% vs 83%; P=0.508), disease‐specific survival (86% vs 84%; P=0.549), or overall survival (77% vs 75%; P=0.901). Conclusions In this large cohort of patients with endometrial cancer, no significant associations were found between use of statins and endometrial cancer survival.

show abstract

Section: Discussionmentioning

confidence: 91%

An Israeli Gynecologic Oncology Group study of statin use and endometrial cancer prognosis

Segev

Gemer

Helpman

et al. 2019

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Seven studies involving 5,449 patients with endocrine-related gynecologic cancers investigated the association between statin use and overall survival (OS) [30, 32–34, 37–39]. The pooled data showed that statin use was associated with improved OS (HR, 0.71; 95% CI, 0.63 to 0.80).…”

Section: Resultsmentioning

confidence: 99%

“…Three studies involving 3,460 patients with endometrial cancer evaluated the association between statin use and OS [30, 32, 33]. The pooled data showed improved OS in statin users, though the data supporting this association was not as robust (HR, 0.83; 95% CI, 0.69 to 1.01) (Figure 3).…”

Section: Resultsmentioning

confidence: 99%

Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis

Xie

Huang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Previous studies investigating the association between statin use and survival outcomes in gynecologic cancers have yielded controversial results. We conducted a systematic review and meta-analysis to evaluate the association based on available evidence. We searched the databases of the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and PubMed from inception to January 2017. Studies that evaluated the association between statin use and survival outcomes in gynecologic cancers were included. Pooled hazard ratios (HRs) for overall survival, disease-specific survival and progression-free survival were calculated using a fixed-effects model. A total of 11 studies involving more than 6,920 patients with endocrine-related gynecologic cancers were identified. In a meta-analysis of 7 studies involving 5,449 patients with endocrine-related gynecologic cancers, statin use was linked to improved overall survival (HR, 0.71; 95% confidence interval [CI], 0.63 to 0.80) without significant heterogeneity (I2 = 33.3%). Statin users also had improved disease-specific survival (3 studies, HR, 0.72; 95% CI, 0.58 to 0.90, I2 = 35.1%) and progression-free survival (3 studies, HR, 0.68; 95% CI, 0.49 to 0.93, I2 = 33.6%) in endocrine-related gynecologic cancers. Our findings support that statin use has potential survival benefits for patients with endocrine-related gynecologic cancers. Further large-scale prospective studies are required to validate our findings.

show abstract

“…Specifically, Statins, well-known inhibitors of HMGCR, have been clinically correlated to prolonged survival expectancy among cancer sufferers, such as endometrial cancer [155] and esophageal adenocarcinoma [156]. Moreover, lower risk of tumor initiation or dissemination have been observed in a variety of cancer types following the administration of Statins, revealing a great possibility to expand its therapeutic indications towards tumorous field.…”

Section: Functions Of Ampk Signaling Components In Tumorigenesismentioning

confidence: 99%

Functional characterization of AMP-activated protein kinase signaling in tumorigenesis

Cheng

Zhang

et al. 2016

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

AMP-activated protein kinase (AMPK) is a ubiquitously expressed metabolic sensor among various species. Specifically, cellular AMPK is phosphorylated and activated under certain stressful conditions, such as energy deprivation, in turn to activate diversified downstream substrates to modulate the adaptive changes and maintain metabolic homeostasis. Recently, emerging evidences have implicated the potential roles of AMPK signaling in tumor initiation and progression. Nevertheless, a comprehensive description on such topic is still in scarcity, especially in combination of its biochemical features with mouse modeling results to elucidate the physiological role of AMPK signaling in tumorigenesis. Hence, we performed this thorough review by summarizing the tumorigenic role of each component along the AMPK signaling, comprising of both its upstream and downstream effectors. Moreover, their functional interplay with the AMPK heterotrimer and exclusive efficacies in carcinogenesis were chiefly explained among genetically altered mice models. Importantly, the pharmaceutical investigations of AMPK relevant medications have also been highlighted. In summary, in this review, we not only elucidate the potential functions of AMPK signaling pathway in governing tumorigenesis, but also potentiate the future targeted strategy aiming for better treatment of aberrant metabolism-associated diseases, including cancer.

show abstract

Statin use and survival in elderly patients with endometrial cancer

Cited by 26 publications

References 13 publications

An Israeli Gynecologic Oncology Group study of statin use and endometrial cancer prognosis

An Israeli Gynecologic Oncology Group study of statin use and endometrial cancer prognosis

Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis

Functional characterization of AMP-activated protein kinase signaling in tumorigenesis

Contact Info

Product

Resources

About